Trials
(Apr 2021)
Conducting clinical trials during the COVID-19 pandemic—a collaborative trial network response
Laura Robison,
Yeoungjee Cho,
Andrea K. Viecelli,
David W. Johnson,
Carmel M. Hawley,
Andrea Valks,
Peta-Anne Paul-Brent,
Ruth Stastny,
Julie Varghese,
Charani Kiriwandeniya,
Elaine M. Pascoe,
Liza A. Vergara,
Magid A. Fahim,
Neil Boudville,
Rathika Krishnasamy,
Donna Reidlinger,
on behalf of the Australasian Kidney Trials Network
Affiliations
Laura Robison
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Yeoungjee Cho
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Andrea K. Viecelli
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
David W. Johnson
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Carmel M. Hawley
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Andrea Valks
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Peta-Anne Paul-Brent
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Ruth Stastny
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Julie Varghese
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Charani Kiriwandeniya
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Elaine M. Pascoe
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Liza A. Vergara
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Magid A. Fahim
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Neil Boudville
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Rathika Krishnasamy
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
Donna Reidlinger
Australasian Kidney Trials Network, The University of Queensland, Level 5, Translational Research Institute
on behalf of the Australasian Kidney Trials Network
DOI
https://doi.org/10.1186/s13063-021-05200-0
Journal volume & issue
Vol. 22,
no. 1
Abstract
Read online
Abstract The unprecedented demand placed on healthcare systems from the COVID-19 pandemic has forced a reassessment of clinical trial conduct and feasibility. Consequently, the Australasian Kidney Trials Network (AKTN), an established collaborative research group known for conducting investigator-initiated global clinical trials, had to efficiently respond and adapt to the changing landscape during COVID-19. Key priorities included ensuring patient and staff safety, trial integrity and network sustainability for the kidney care community. New resources have been developed to enable a structured review and contingency plan of trial activities during the pandemic and beyond.
WeChat QR code
Close
